Intensified Total Neoadjuvant Therapy Improves Survival in High-Risk Rectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Intensified Total Neoadjuvant Therapy Improves Survival in High-Risk Rectal Cancer
A Chinese phase III trial of 458 patients with high-risk locally advanced rectal cancer found that integrating long-course radiotherapy with uninterrupted capecitabine and oxaliplatin chemotherapy (doublet-LC TNT) achieved 3-year disease-free survival of